BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 25
• 26
• 27
• 28
• 29

• BioForest

  Cardiac Insight Continues Steady Beat Of Progress With New $4.5 Million Investment And Attracts Prestigious Healthcare M&A Executive, Clifford J. Stocks, To Its Board Of Directors

  September 6, 2017

   · 

  3 min read
• Business

  Nuevolution Announces Its Results For The Fourth Quarter And Full Year 2016/17

  September 6, 2017

   · 

  3 min read
• Groundbreaking Physiotherapy Device Licensed By BGN Technologies Is Deployed By Spanish Real Sociedad Soccer Club

  September 6, 2017

   · 

  3 min read
• Drug Development

  BioMarin Presents Interim Data Of Phase I/II Study Of BMN 250 For Treatment Of Sanfilippo B Syndrome (MPS IIIB) At 13th International Congress Of Inborn Errors Of Metabolism (ICIEM) 2017

  September 6, 2017

   · 

  7 min read
• Business

  Bay Area’s Notable Labs Banks $10 Million to Advance Personalized Cancer Treatments

  September 6, 2017

   · 

  2 min read
• FDA

  FDA Approves Guerbet’s Dotarem (Gadoterate Meglumine) For Pediatric Patients Younger Than Two Years

  September 6, 2017

   · 

  6 min read
• Policy

  AbbVie Submits New Drug Application To U.S. FDA For Investigational Oral Treatment Elagolix For The Management Of Endometriosis With Associated Pain

  September 6, 2017

   · 

  7 min read
• Pharm Country

  Bristol-Myers Squibb Employees Ride Across The U.S. To Raise Money To Support Cancer Research By Stand Up To Cancer

  September 6, 2017

   · 

  3 min read
• Drug Development

  MiNA Announces Publication Of Pre-Clinical Data Supporting On-Target Mechanism Of Action Of Clinical Candidate MTL-CEBPA

  September 6, 2017

   · 

  2 min read
• Biotech Bay

  CEO of Bay Area’s Iovance Biotherapeutics Sees TIL Technology as Best Immunotherapy Option for Treating Solid Tumors

  September 6, 2017

   · 

  3 min read